Cambridge Innovation Capital is an established VC firm embedded in the UK technology ecosystem with privileged access to the University of Cambridge. The firm manages over £600m of capital and invests across deep tech and life sciences.
Molten Ventures led the Series B round with participation from Altair and existing investors to accelerate the development of Deltaflow.OS.
"Solving quantum error correction – one of the defining scientific challenges of our times – will enable quantum computers to accurately simulate the true complexity of nature. Armed with useful quantum computers, humans will enter the Quantum Age, where we go from slow trial and error to solve complex problems to an era of rapid design using quantum computers. We haven’t even begun to imagine the many ways such technology will positively transform our world."
The Series A round was backed by Syncona Investment Management and Cambridge Innovation Capital to support pipeline progression and team expansion.
"I believe that Mosaic is ideally positioned to resolve the complexity of cancer, to discover and develop targeted therapies that address areas of high unmet need. The people, platform, connection to a world-leading genomics research institute, and strong investor partnerships are truly best in class. To receive funding from such high calibre investors is testament to the potential of Mosaic’s technology and multidisciplinary team, as well as the exceptional support provided by the Wellcome Sanger Institute."
Amadeus Capital Partners and Octopus Ventures co-led the seed round to support product development and team expansion.
"The entire team is very excited about the opportunity that this financing has given us to develop Unlikely AI and its technology, and we are delighted to partner with our new investors."
The seed round was co-led by Cambridge Innovation Capital and Oxford Science Enterprises to accelerate the development of photonic artificial intelligence processors.
"Salience Labs brings together deep domain expertise in photonics, electronics and CMOS manufacture."
The financing round was co-led by Tencent and Flerie Invest to support Phase 1b clinical studies and pipeline expansion.
"This major fundraise is a substantial validation of both our team and our world-leading technology. We are fortunate to have the support from new and current investors who have recognised the importance of the microbiome's therapeutic potential and Microbiotica's unique capabilities."
